The effect of adding rituximab to high dose chemotherapy

U Vitolo; A Chiappella; G Rossi; E Angelucci; M Liberati; E Liberati

doi:10.4081/hmr.v2i7.426

Authors

High-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) has been proved to be an effective salvage treatment in chemo-sensitive relapsed patients for both aggressive and indolent lymphomas. Since that, many investigators have extended this approach as part of the initial therapy of patients with aggressive lymphomas, especially those considered at poor prognosis, with conflicting results in randomized studies. Indeed a recent meta-analyses of up to 11 randomized trials in aggressive lymphomas, showed a similar OS in patients receiving first-line HDC + ASCT or standard chemotherapy.

Supporting Agencies

Vitolo, U., Chiappella, A., Rossi, G., Angelucci, E., Liberati, M., & Liberati, E. (2009). The effect of adding rituximab to high dose chemotherapy. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.426

Download Citation

Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations